GLP-1s and PCOS: The risks nobody's talking about (and why nutrition still wins long-term)
- Laura-Kate Loveridge
- Jul 6
- 2 min read
GLP-1 medications like Ozempic and Wegovy are everywhere right now, and for women with PMOS, the appeal is understandable — insulin resistance sits at the centre of so many PMOS cases, and these drugs were built to target exactly that. But "promising results in a trial" and "right for you long-term" are two very different things. Here's what the evidence actually shows.
The risks worth knowing about:
Digestive side effects are common and can be significant — nausea, vomiting, constipation and bloating are the most frequently reported issues, and for some women they don't fully settle.
Muscle loss and nutrient gaps are a real concern. A review of nearly 460,000 GLP-1 users found 2.1% experienced muscle loss and 12.7% had a new nutritional deficiency diagnosed within six months — most commonly vitamin D and iron (NutraIngredients, citing a Clinical Obesity review, March 2026).
The weight loss doesn't tend to stick without the drug. Trial data on semaglutide found that within a year of stopping, participants regained roughly two-thirds of the weight they'd lost (STEP 1 extension trial, reported in MedCentral, Dec 2025). Current research increasingly describes these medications as a chronic, ongoing therapy rather than a short-term fix — which is a significant thing to weigh up.
They're not licensed specifically for PCOS / PMOS, and long-term safety data in women of reproductive age is still limited.
Fertility and pregnancy timing matters a lot here. GLP-1s can restore ovulation in women who weren't ovulating regularly — which means unplanned pregnancy is a real possibility if contraception isn't in place. At the same time, they aren't considered safe during pregnancy, and most guidance recommends stopping at least one to two months before trying to conceive to let the drug clear your system (WeNatal, Nov 2025). For anyone in the fertility/TTC space, that timing conversation with a specialist isn't optional.
Regulators are still investigating a possible mental health signal. The FDA and EMA have both issued safety communications around a possible link to suicidal ideation and behaviour, though the evidence so far is described as inconclusive (systematic review and meta-analysis, PMC, 2024).
Why nutrition and lifestyle remain the foundation
None of this is about villainising GLP-1s — for some women, under proper medical supervision, they may be part of the picture. But they treat a symptom (insulin resistance) without requiring you to build the habits that actually sustain hormonal balance once treatment stops.
Nutrition, movement, sleep and stress management:
Address the root metabolic drivers of PCOS / PMOS directly, not just the downstream numbers
Don't come with a withdrawal or rebound effect
Support fertility and preconception health without a washout period to plan around
Build habits you keep for life, not a prescription you may need to renew indefinitely
If you're considering a GLP-1, that's a conversation for you and a qualified healthcare professional — not something to decide based on a social post. But if you're looking for the sustainable, foundational piece, that's exactly where nutrition-first support comes in.
Comments